Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Keto5 is a private metabolic health and physician-channel nutrition company that markets exogenous ketone products and ketogenic support programs for weight loss clinics, integrative physicians, and other health professionals. The company focuses on raising blood ketone levels through beta-hydroxybutyrate and medium-chain triglyceride based products, positioning these products as tools to support targeted ketosis, metabolic health, cognitive performance, and weight management. Its commercial portfolio includes products such as XOULTRA, XOGENIUS, and XO8, and the company also promotes a provider network model in which clinicians guide patient use. Keto5 describes its approach as "Adjustable Targeted Adjuvant Ketosis (ATAK)," a branded framework for precision ketone support rather than a drug-development platform. Based on the available evidence, Keto5 appears to be a health and wellness company rather than a traditional biotech or pharmaceutical developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Keto5.